Valneva SE (VALN) Other Non-Current Assets (2020 - 2026)
Valneva SE (VALN) posted quarterly Other Non-Current Assets of $8.6 million for Q1 2026, down 9.26% year-on-year from $9.5 million in Q1 2025, and little changed on a QoQ basis from $8.6 million in Q4 2025.
Valneva SE (VALN) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Other Non-Current Assets for 7 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Assets fell 9.26% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (down 9.26% YoY) and the FY2025 annual result came in at $8.6 million, down 5.61% from the prior year.
- Other Non-Current Assets steadied at $8.6 million in Q1 2026 per VALN's latest filing, from $8.6 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for VALN reached as high as $61.4 million in Q2 2022 and fell as low as $8.4 million in Q3 2025.
- A 5-year average of $13.8 million and a median of $9.5 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets tumbled 85.3% — and 2024, when it advanced 14.07%.
- Year by year, Other Non-Current Assets stood at $9.4 million in 2022, then increased by 2.3% to $9.7 million in 2023, then dropped by 5.29% to $9.2 million in 2024, then decreased by 5.61% to $8.6 million in 2025, then decreased by 0.17% to $8.6 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $8.6 million, $8.6 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 8.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.62 Mn |
| Dec 31, 2025 | 8.64 Mn |
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 9.82 Mn |
| Mar 31, 2025 | 9.50 Mn |
| Dec 31, 2024 | 9.15 Mn |
| Sep 30, 2024 | 8.60 Mn |
| Jun 30, 2024 | 10.30 Mn |
| Mar 31, 2024 | 9.98 Mn |
| Dec 31, 2023 | 9.66 Mn |
| Sep 30, 2023 | 9.36 Mn |
| Jun 30, 2023 | 9.03 Mn |
| Mar 31, 2023 | 9.78 Mn |
| Dec 31, 2022 | 9.44 Mn |
| Sep 30, 2022 | 20.82 Mn |
| Jun 30, 2022 | 61.41 Mn |
| Mar 31, 2022 | 22.21 Mn |
| Dec 31, 2021 | 21.94 Mn |
| Dec 31, 2020 | 22.16 Mn |